[CAS NO. 1800405-30-4] KL1333
PRODUCTS SPECIFICATIONS [1800405-30-4]
DESCRIPTION [1800405-30-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 240.26 |
| Molecular Formula | C14H12N2O2 |
| SMILES | O=C(C1=C2N=C(C(C)C)N1)C(C3=C2C=CC=C3)=O |
1 Publications Citing Use of MCE
Summary
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures [1] [2] .
IC50 & Target
NQO1 [1]
In Vitro
KL1333 is a potent modulator of the cellular levels of NAD⁺, a central co-enzyme in the cell’s energy metabolism. Elevated NAD+ levels triggers the activation of SIRT1 and AMPK, and subsequently activates PGC-1α [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04643249 | Abliva AB |
Mitochondrial Disease
|
November 10, 2020 | Phase 1 |
| NCT03888716 | Abliva AB |
Mitochondrial Diseases|Mitochondrial Respiratory Chain Deficiencies|MELAS Syndrome|Mitochondrial Myopathies
|
March 18, 2019 | Phase 1 |
| NCT03056209 | Yungjin Pharm. Co., Ltd. |
MELAS Syndrome|Mitochondrial Respiratory Chain Deficiencies
|
June 26, 2017 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 416.22 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.1622 mL | 20.8108 mL | 41.6216 mL |
| 5 mM | 0.8324 mL | 4.1622 mL | 8.3243 mL |
| 10 mM | 0.4162 mL | 2.0811 mL | 4.1622 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.41 mM); Clear solution
References
- [1] Seo KS, et al. KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts. Front Neurol. 2018;9:552. Published 2018 Jul 5.
- [2] Lee HS, et al. KL1333, a derivative of β-lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures. Biomed Pharmacother. 2020;126:110068.